Ares-Serono Earnings Down Due To High R&D

26 March 1995

As a result of reporting lower earnings, due to high research and development investment and lower sales in some markets, for the year ended December 31, 1994, Swiss company Ares-Serono's share price fell 4.6%. Earnings from continued operations totaled $38.6, down 61% on 1993. R&D spending increased 21.7% to $138.3 million, and sales reached $636.8 million, a decline of 5%, mainly due to lower turnover in Spain and Italy. Without the negative impact of these two markets, sales would have increased 22.3%.

The company says that fourth-quarter 1994 sales and earnings were also influenced by a shortage in Europe and the USA of some of its products. This shortage, combined with lower sales in Italy, lead to a temporarily unfavorable product mix in terms of profitability.

Following the completion of Phase III clinical trials in the USA, the US Food and Drug Administration approved a Treatment Investigational New Drug program in December 1994 for the use of Ares-Serono's mammalian cell-derived recombinant human growth hormone Serostim in HIV-associated catabolism, which is a leading cause of death in people suffering with AIDS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight